Artificial Intelligence

A new partnership moves AI from isolated tasks to integrated workflows, promising to solve the ROI problem that has plagued enterprise adoption.

Beijing has placed AI-powered robots at the core of its national strategy, aiming to reshape global manufacturing and accelerate a new technological race.

The 2026 Ellis Island Medals of Honor recipients are announced, celebrating leaders from OpenAI, Mercedes-Benz, and more for their global impact.

Recognized on the CB Insights AI 100 list, Rhino Federated Computing pioneers a new era of secure, decentralized AI for highly regulated industries.

Netskope's new AgentSkope platform uses AI agents to automate security tasks, aiming to solve the industry's crippling alert fatigue and analyst burnout.

JAGGAER launches JAI, an AI assistant promising to slash support tickets and automate complex buying decisions, pushing procurement toward an autonomous future.

NImmune Biopharma's oral drug NIM-1324 shows promising safety and efficacy, targeting a novel pathway to treat IBD and a host of other diseases.

With 21% of voice actors reporting job losses to AI, a national association is taking its fight to D.C. to demand policy action and protect human creativity.

Forrester's new report highlights Airia as enterprises grapple with governing the new wave of autonomous, agentic AI systems that defy old rules.

With compliance costs soaring, Spring Labs' $5M funding round will scale its AI agents to automate the execution of regulatory tasks for financial firms.

A historic 142 deals and $1.67 trillion in assets changed hands in Q1 2026, as private equity, tech, and global ambitions fuel a record consolidation wave.

Diagnostic leader Bracco enters the cell therapy market with BubbleGen, a novel microbubble tech that promises to streamline complex manufacturing.

A new national agreement brings QuVa Pharma's AI-powered drug diversion software to thousands of hospitals, promising a high-tech solution to a hidden crisis.

Viant's acquisition of TVision challenges industry giants by pricing TV ads on actual viewership, moving beyond impressions to verifiable human attention.

A biotech firm is making waves with a non-viral, redosable gene delivery system showing promise for DMD and hemophilia, challenging the industry's reliance on viruses.

A new blood test could tell you if GLP-1 drugs will work for you before you start, a major leap for precision medicine in the booming obesity market.

With a star-studded new advisory board, Pilatus Biosciences accelerates its attack on cancer's metabolic defenses with its lead drug, PLT012.

Sensei Biotherapeutics begins a key trial for PIKTOR, a novel oral therapy aiming to outsmart cancer resistance in patients with advanced breast cancer.

Bridge Growth Partners launches a massive continuation fund for its real-time data platform, signaling a new gold rush for AI's foundational technology.

Minerva Neurosciences launches a pivotal Phase 3 trial for roluperidone, a potential first-in-class drug for the untreated negative symptoms of schizophrenia.